Indoco Remedies (INDOCO) Stock Overview
Manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
INDOCO Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Indoco Remedies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹257.95 |
| 52 Week High | ₹355.00 |
| 52 Week Low | ₹190.00 |
| Beta | 0.49 |
| 1 Month Change | -5.58% |
| 3 Month Change | -3.24% |
| 1 Year Change | -18.42% |
| 3 Year Change | -34.65% |
| 5 Year Change | -11.02% |
| Change since IPO | 390.71% |
Recent News & Updates
Recent updates
Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Sep 05
Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Jul 27Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
Jul 01Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Jan 29
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
Jan 24Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Oct 27Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
May 24Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
Jan 26Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Jan 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Sep 16Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
May 21Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Aug 31Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Jul 04Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Jul 02Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Jun 10Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Mar 25Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price
Mar 09What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?
Feb 22Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?
Feb 07Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 17Shareholder Returns
| INDOCO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.3% | 0.5% | -0.2% |
| 1Y | -18.4% | -0.4% | 2.3% |
Return vs Industry: INDOCO underperformed the Indian Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: INDOCO underperformed the Indian Market which returned 2.3% over the past year.
Price Volatility
| INDOCO volatility | |
|---|---|
| INDOCO Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: INDOCO has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INDOCO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 6,000 | Sundeep Bambolkar | www.indoco.com |
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services.
Indoco Remedies Limited Fundamentals Summary
| INDOCO fundamental statistics | |
|---|---|
| Market cap | ₹23.80b |
| Earnings (TTM) | -₹1.11b |
| Revenue (TTM) | ₹17.25b |
Is INDOCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDOCO income statement (TTM) | |
|---|---|
| Revenue | ₹17.25b |
| Cost of Revenue | ₹5.58b |
| Gross Profit | ₹11.68b |
| Other Expenses | ₹12.78b |
| Earnings | -₹1.11b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.98 |
| Gross Margin | 67.68% |
| Net Profit Margin | -6.41% |
| Debt/Equity Ratio | 96.3% |
How did INDOCO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/27 17:35 |
| End of Day Share Price | 2025/11/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indoco Remedies Limited is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |